Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Longitudinal Evaluation of Early Breast Cancer With Adjuvant Real-World Data in the Post-CDK4/6 Inhibitor Approval Era: Analysis Using Integra PrecisionQ Oncology Database (LEEWARD)

NCT07647042 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07647042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07647042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Longitudinal Evaluation of Early Breast Cancer With Adjuvant Real-World Data in the Post-CDK4/6 Inhibitor Approval Era: Analysis Using Integra PrecisionQ Oncology Database (LEEWARD)
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
March 31, 2026
Completion date
April 30, 2026
Enrollment
750 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer